Enfermedades contagiosas

Examinar

Mostrando 1 - 4 de 4

Defunciones por COVID-19: Distribución por edad y universalidad de la cobertura médica en 22 países
(Revista Panamericana de Salud Pública, No. 45, 2021) Fantin, Romain Clement; Brenes Camacho, Gilbert; Barboza Solís, Cristina
Objetivo. Relacionar la distribución etaria estandarizada de las defunciones por COVID-19 en 22 países americanos y europeos, con diferentes indicadores de las características de las poblaciones y de los sistemas de salud. Métodos. Las distribuciones de las defunciones por COVID-19 por grupo etario en 22 países americanos y europeos fueron estandarizadas sobre la pirámide de edades de la población mundial. Se calcularon las correlaciones entre la proporción estandarizada de personas de menos de 60 años dentro de las personas fallecidas y cada uno de los seis indicadores. Resultados. Se evidenció la existencia de diferencias importantes de distribución por grupo etario entre los países después de haber estandarizado sobre la pirámide de edades a nivel mundial, siendo la proporción de personas de menos de 60 años superior en América Latina y Estado Unidos que en Canadá o Europa occidental. La proporción estandarizada de personas de menos de 60 años dentro de las personas fallecidas por COVID-19 está fuertemente correlacionada con la universalidad de una cobertura médica de calidad (r=-0,92, p<0,01). Esta relación se mantuvo significativa después de haber ajustado sobre los otros indicadores analizados. Conclusión. Se propone que las debilidades de la cobertura médica de la población podrían haber creado una mayor letalidad en las poblaciones de menos de 60 años en América Latina y en los Estados Unidos.
The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence
(JMIR Public Health and Surveillance, vol.8(5), 2022) Rosero Bixby, Luis
Background: The Costa Rican COVID-19 vaccination program has used Pfizer-BioNTech and Oxford-AstraZeneca vaccines. Real-world estimates of the effectiveness of these vaccines to prevent hospitalizations range from 90%-98% for two doses and from 70%-91% for a single dose. Almost all of these estimates predate the Delta variant. Objective: The aim of this study is to estimate the dose-dependent effectiveness of COVID-19 vaccines to prevent severe illness in real-world conditions in Costa Rica, after the Delta variant became dominant. Methods: This observational study is a secondary analysis of hospitalization prevalence. The sample is all 3.67 million adult residents living in Costa Rica by mid-2021. The study is based on public aggregated data of 5978 COVID-19–related hospital records from September 14, 2021, to October 20, 2021, and 6.1 million vaccination doses administered to determine hospitalization prevalence by dose-specific vaccination status. The intervention retrospectively evaluated is vaccination with Pfizer-BioNTech (78%) and Oxford-AstraZeneca (22%). The main outcome studied is being hospitalized. Results: Vaccine effectiveness against hospitalization (VEH) was estimated as 93.4% (95% CI 93.0-93.9) for complete vaccination and 76.7% (95% CI 75.0-78.3) for single-dose vaccination among adults of all ages. VEH was lower and more uncertain among older adults aged ≥58 years: 92% (95% CI 91%-93%) for those who had received full vaccination and 64% (95% CI 58%-69%) for those who had received partial vaccination. Single-dose VEH declined over time during the study period, especially in the older age group. Estimates were sensitive to possible errors in the population count used to determine the residual number of unvaccinated people when vaccine coverage is high. Conclusions: The Costa Rican COVID-19 vaccination program that administered Pfizer-BioNTech and Oxford-AstraZeneca vaccines seems to be highly effective at preventing COVID-19–related hospitalization after the Delta variant became dominant. Even a single dose seems to provide some degree of protection, which is good news for people whose second dose of the Pfizer-BioNTech vaccine was postponed several weeks to more rapidly increase the number of people vaccinated with a first dose. Timely monitoring of vaccine effectiveness is important to detect eventual failures and motivate the public to get vaccinated by providing information regarding the effectiveness of the vaccines.
Excess mortality from COVID 19 in Costa Rica: a registry based study using Poisson regression
(The Lancet Regional Health - Americas, Vol.20, 2023) Fantin, Romain Clement; Barboza Solís, Cristina; Hildesheim, Allan; Herrero, Rolando
Excess mortality from COVID 19 in Costa Rica: a registry based study using Poisson regression Romain Fantin,a ,b ,c ,∗ Cristina Barboza-Solís,c Allan Hildesheim,b and Rolando Herrerob a Centro Centroamericano de Población, Universidad de Costa Rica, San Pedro, Costa Rica b Agencia Costarricense de Investigaciones Biomédicas – Fundación Inciensa, San José, Costa Rica c Facultad de Odontología, Universidad de Costa Rica, San Pedro, Costa Rica Summary Background Official death toll related to COVID-19 has been considerably underestimated in reports from some Latin American countries. This study aimed to analyze the mortality associated with the COVID-19 pandemic in Costa Rica between March 2020 and December 2021. Methods A registry based study based on 2017–2021 data from the National Institute of Statistics and Census was designed (N = 128,106). Excess deaths were defined by the WHO as “the difference in the total number of deaths in a crisis compared to those expected under normal conditions”; and were estimated using a Poisson regression, and mortality and years of potential life lost (YPLL) rates were calculated. Findings The COVID-19 pandemic represented 15% of the deaths in Costa Rica between March 2020 and December 2021. The mortality rate related to COVID-19 was 83 per 100,000 person-years. Between March and July 2020 (low- incidence period), observed number of deaths was 9%-lower than expected, whereas it was 15% and 24% higher than expected between July 2020 and March 2021 (high incidence period - no vaccination), and between March 2021 and December 2021 (high incidence period – progressive vaccination) respectively. Between July 2020 and December 2021, excess deaths observed and COVID-19 deaths reported were comparable (7461 and 7620 respectively). Nevertheless, there were more deaths than expected for conditions that predispose to COVID-19 deaths. YPLL and mortality rates increased with age, but significant excess deaths were observed in all age-groups older than 30–39 years. No large differences were noted by districts’ socioeconomic characteristics although excess death rate was lower in rural compared to urban areas
The mathematics of the reproduction number R for Covid-19: A primer for demographers
(Vienna Yearbook of Population Research 20 (online first), 2022) Rosero Bixby, Luis; Miller, Timothy
The reproduction number R is a key indicator used to monitor the dynamics of Covid-19 and to assess the e ects of infection control strategies that frequently have high social and economic costs. Despite having an analog in demography’s “net reproduction rate” that has been routinely computed for a century, demographers may not be familiar with the concept and measurement of R in the context of Covid-19. This article is intended to be a primer for understanding and estimating R in demography. We show that R can be estimated as a ratio between the numbers of new cases today divided by the weighted average of cases in previous days. We present two alternative derivations for these weights based on how risks have changed over time: constant vs. exponential decay. We then provide estimates of these weights, and demonstrate their use in calculating R to trace the course of the first pandemic year in 53 countries.

Examinar

Examinando Enfermedades contagiosas por Materia "COVID-19"

Resultados por página

Opciones de ordenación